GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
41.15
+0.35 (0.86%)
Jun 5, 2025, 4:00 PM - Market closed
GSK Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$593,563
Profits / Employee
$59,358
Market Cap
83.31B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GSK News
- 3 days ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire
- 8 days ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 8 days ago - GSK, Spero to stop urinary tract infection drug trial due to early success - Reuters
- 8 days ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire
- 13 days ago - Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) - Business Wire
- 14 days ago - GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung' - Reuters
- 17 days ago - GSK's Blood-Cancer Treatment Combinations Approved in Japan - WSJ
- 22 days ago - GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - WSJ